AI Article Synopsis
- Researchers developed recombinant baculovirus and virus-like particle vaccines targeting CST1 and ROP18 antigens to assess their ability to protect mice from a Toxoplasma gondii infection.
- Both CST1 and ROP18 vaccines successfully generated similar levels of specific IgG and IgA antibodies, showing the vaccines were effective in prompting immune responses.
- However, the CST1 vaccine proved to be more effective than the ROP18 vaccine by activating more antibody-secreting cells, enhancing B cell activity, and significantly reducing brain cysts and weight loss in mice, indicating its potential for better toxoplasmosis vaccine development.
Article Abstract
To evaluate the protective efficacy induced by heterologous immunization with recombinant baculoviruses or virus-like particles targeting the CST1 and ROP18 antigens of .: Recombinant baculovirus and virus-like particle vaccines expressing CST1 or ROP18 antigens were developed to evaluate protective immunity in mice upon challenge infection with 450 (ME49). Immunization with CST1 or ROP18 vaccines induced similar levels of -specific IgG and IgA responses. Compared with ROP 18, CST1 vaccine showed better antibody-secreting cell response, germinal center B cell activation, and significantly reduced brain cyst burden and body weight loss. Our findings suggest that CST1 heterologous immunization elicited better protection than ROP18, providing important insight into improving the toxoplasmosis vaccine design strategy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11520538 | PMC |
| http://dx.doi.org/10.1080/17435889.2024.2403333 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!